

UNITED STATES SECURITIES AND EXCHANGE
COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Hyare Parvinder S</u> (Last) (First) (Middle) <u>SUNESIS PHARMACEUTICALS, INC.</u> <u>395 OYSTER POINT BOULEVARD, SUITE 400</u> (Street) <u>SOUTH SAN FRANCISCO CA 94080</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>01/01/2021</u>	3. Issuer Name and Ticker or Trading Symbol <u>SUNESIS PHARMACEUTICALS INC [SNSS]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>See Remarks</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Stock</u>	<u>960</u>	<u>D</u>	

Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>Stock Option (Right to Buy)</u>	<u>(1)</u>	<u>11/30/2025</u>	<u>Common Stock</u>	<u>2,400</u>	<u>61.8</u>	<u>D</u>	
<u>Stock Option (Right to Buy)</u>	<u>(1)</u>	<u>11/30/2026</u>	<u>Common Stock</u>	<u>3,500</u>	<u>40</u>	<u>D</u>	
<u>Stock Option (Right to Buy)</u>	<u>(1)</u>	<u>07/10/2024</u>	<u>Common Stock</u>	<u>2,695</u>	<u>26.2</u>	<u>D</u>	
<u>Stock Option (Right to Buy)</u>	<u>(2)</u>	<u>12/29/2027</u>	<u>Common Stock</u>	<u>6,999</u>	<u>36.9</u>	<u>D</u>	
<u>Stock Option (Right to Buy)</u>	<u>(3)</u>	<u>12/31/2028</u>	<u>Common Stock</u>	<u>6,999</u>	<u>4.16</u>	<u>D</u>	
<u>Stock Option (Right to Buy)</u>	<u>(4)</u>	<u>03/29/2029</u>	<u>Common Stock</u>	<u>2,749</u>	<u>12.15</u>	<u>D</u>	
<u>Stock Option (Right to Buy)</u>	<u>(5)</u>	<u>07/31/2029</u>	<u>Common Stock</u>	<u>749</u>	<u>8.6</u>	<u>D</u>	
<u>Stock Option (Right to Buy)</u>	<u>(6)</u>	<u>03/31/2030</u>	<u>Common Stock</u>	<u>28,499</u>	<u>4.15</u>	<u>D</u>	

Explanation of Responses:

1. Fully vested.

2. One fourth (1/4th) of the shares shall vest one (1) year from the Vesting Commencement Date of December 29, 2017. Thereafter, one forty-eighth (1/48th) of the shares granted shall vest monthly over the next thirty-six (36) months.

3. One fourth (1/4th) of the shares shall vest one (1) year from the Vesting Commencement Date of December 31, 2018. Thereafter, one forty-eighth (1/48th) of the shares granted shall vest monthly over the next thirty-six (36) months.

4. One fourth (1/4th) of the shares shall vest one (1) year from the Vesting Commencement Date of March 29, 2019. Thereafter, one forty-eighth (1/48th) of the shares granted shall vest monthly over the next thirty-six (36) months.

5. One fourth (1/4th) of the shares shall vest one (1) year from the Vesting Commencement Date of July 31, 2019. Thereafter, one forty-eighth (1/48th) of the shares granted shall vest monthly over the next thirty-six (36) months.

6. One fourth (1/4th) of the shares shall vest one (1) year from the Vesting Commencement Date of March 31, 2020. Thereafter, one forty-eighth (1/48th) of the shares granted shall vest monthly over the next thirty-six (36) months.

Remarks:

Interim Chief Executive Officer

/s/ Parvinder S. Hyare

01/07/2021

** Signature of Reporting
Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.